Literature DB >> 10580801

IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis.

Y Okuda1, S Sakoda, H Fujimura, Y Saeki, T Kishimoto, T Yanagihara.   

Abstract

We investigated the role of IL-6 in myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental autoimmune encephalomyelitis (EAE) using IL-6-deficient mice and found that IL-6-deficient mice were resistant to active induction of EAE, but that the treatment of those mice with IL-6 during the preclinical phase caused typical EAE. We also found that both wild-type and IL-6-deficient mice were resistant to passive transfer of EAE by lymphocytes from IL-6-deficient mice, but that passive transfer of lymphocytes from wild-type mice induced typical EAE in IL-6-deficient mice. Histological abnormalities of the central nervous system (CNS) in those IL-6-deficient mice with EAE were similar to those in wild-type mice with EAE. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis revealed no difference in the production of inflammatory cytokines such as IL-1beta, IL-2, TNF-alpha, and IFN-gamma in the CNS of IL-6-deficient mice with EAE as compared to the CNS of wild-type mice with EAE. These results indicated that IL-6 might be an important factor in the induction phase, but might have little influence on the effector phase of EAE. We further estimated the production of cytokines in MOG-stimulated lymph node (LN) cells by enzyme-linked immunosorbent assay. Increased IL-4 and IL-10 production and reduced IL-2 and IFN-gamma production were observed in LN cells from IL-6-deficient mice as compared to LN cells from wild-type mice. These results suggested that a shift of T cell responses from Thl to Th2 might explain the resistance of IL-6-deficient mice to EAE. Taken together, IL-6 may play a crucial role in the induction phase of EAE by modulating Th1/Th2 balance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580801     DOI: 10.1016/s0165-5728(99)00139-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  37 in total

1.  Viral induction of central nervous system innate immune responses.

Authors:  J D Rempel; L A Quina; P K Blakely-Gonzales; M J Buchmeier; D L Gruol
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Treatment of MOG antibody associated disorders: results of an international survey.

Authors:  D H Whittam; V Karthikeayan; E Gibbons; R Kneen; S Chandratre; O Ciccarelli; Y Hacohen; J de Seze; K Deiva; R Q Hintzen; B Wildemann; S Jarius; I Kleiter; K Rostasy; P Huppke; B Hemmer; F Paul; O Aktas; A K Pröbstel; G Arrambide; M Tintore; M P Amato; M Nosadini; M M Mancardi; M Capobianco; Z Illes; A Siva; A Altintas; G Akman-Demir; L Pandit; M Apiwattankul; J Y Hor; S Viswanathan; W Qiu; H J Kim; I Nakashima; K Fujihara; S Ramanathan; R C Dale; M Boggild; S Broadley; M A Lana-Peixoto; D K Sato; S Tenembaum; P Cabre; D M Wingerchuk; B G Weinshenker; B Greenberg; M Matiello; E C Klawiter; J L Bennett; A I Wallach; I Kister; B L Banwell; A Traboulsee; D Pohl; J Palace; M I Leite; M Levy; R Marignier; T Solomon; M Lim; S Huda; A Jacob
Journal:  J Neurol       Date:  2020-07-04       Impact factor: 4.849

3.  PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis.

Authors:  Christina Van; Michael C Condro; Kenny Lov; Ruoyan Zhu; Patrick T Ricaflanca; Henly H Ko; Anna L Diep; Anh Q Hoang; Joseph Pisegna; Hermann Rohrer; James A Waschek
Journal:  J Mol Neurosci       Date:  2018-07-30       Impact factor: 3.444

4.  Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine.

Authors:  I S Leal; M Flórido; P Andersen; R Appelberg
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 5.  Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.

Authors:  Tobias D Merson; Michele D Binder; Trevor J Kilpatrick
Journal:  Neuromolecular Med       Date:  2010-03-30       Impact factor: 3.843

6.  Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.

Authors:  Roberta Brambilla; Trikaldarshi Persaud; Xianchen Hu; Shaffiat Karmally; Valery I Shestopalov; Galina Dvoriantchikova; Dmitry Ivanov; Lubov Nathanson; Scott R Barnum; John R Bethea
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis.

Authors:  Georgina Galicia; Ahmad Kasran; Catherine Uyttenhove; Kathleen De Swert; Jacques Van Snick; Jan L Ceuppens
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

Review 8.  Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.

Authors:  Tanuja Chitnis; Samia J Khoury
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

Authors:  Thomas Korn; Estelle Bettelli; Wenda Gao; Amit Awasthi; Anneli Jäger; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

Review 10.  More stories on Th17 cells.

Authors:  Alexandre S Basso; Hilde Cheroutre; Daniel Mucida
Journal:  Cell Res       Date:  2009-04       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.